The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus

Infection and Immunity

Volumn 76, Issue 10, 2008, Pages 4574-4580

  Spellberg, Brad ^a,b,d   Ibrahim, Ashraf S ^a,b   Yeaman, Michael R ^a,b   Lin, Lin ^a   Fu, Yue ^a,b   Avanesian, Valentina ^a   Bayer, Arnold S ^a,b   Filler, Scott G ^a,b   Lipke, Peter ^c   Otoo, Henry ^c,e   Edwards Jr , John E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d RB2 ^*  (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTISERUM; FREUND ADJUVANT; FUNGUS VACCINE; RECOMBINANT N TERMINUS OF THE CANDIDAL SURFACE ADHESIN ALS3P N; TETANUS TOXOID; TETGUARD; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IMMUNE RESPONSE; IMMUNIZATION; INFECTION SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROVOCATION TEST; PSEUDOMONAS AERUGINOSA; SINGLE DRUG DOSE; SPLEEN CELL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; SURVIVAL; T LYMPHOCYTE; TAIL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ALUMINUM HYDROXIDE; ANIMALS; B-LYMPHOCYTES; BACTEREMIA; COAGULASE; COLONY COUNT, MICROBIAL; CROSS REACTIONS; FUNGAL PROTEINS; FUNGAL VACCINES; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 53649092493     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00700-08     Document Type: Article

References (39)

1. Anonymous. 21 November 2003, posting date. Annex 1: guidelines on nonclinical evaluation of vaccines. World Health Organization, Geneva, Switzerland. http://www.who.int/biologicals/publications/trs/areas/vaccines/dna/ Annex%201_DNA%20vaccines.pdf.
2. Andes, D., and W. A. Craig. 2006. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models. Antimicrob. Agents Chemother. 50:243-249.
3. Arias, C. A., K. V. Singh, D. Panesso, and B. E. Murray. 2007. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates. Antimicrob. Agents Chemother. 51:2043-2047.
4. Baddour, L. M., G. D. Christensen, M. G. Hester, and A. L. Bisno. 1984. Production of experimental endocarditis by coagulase-negative staphylococci: variability in species virulence. J. Infect. Dis. 150:721-727.
5. Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.
6. Chambers, H. F. 2005. Community-associated MRSA - resistance and virulence converge. N. Engl. J. Med. 352:1485-1487.
7. Cheung, A. L., A. S. Bayer, J. Peters, and J. I. Ward. 1987. Analysis by gel electrophoresis, Western blot, and peptide mapping of protein A heterogeneity in Staphylococcus aureus strains. Infect. Immun. 55:843-847.
8. Christensen, G. D., A. L. Bisno, J. T. Parisi, B. McLaughlin, M. G. Hester, and R. W. Luther. 1982. Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis. Ann. Intern. Med. 96:1-10.
9. Deslouches, B., I. A. Gonzalez, D. DeAlmeida, K. Islam, C. Steele, R. C. Montelaro, and T. A. Mietzner. 2007. De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J. Antimicrob. Chemother. 60:669-672.
10. Fridkin, S. K., J. C. Hageman, M. Morrison, L. T. Sanza, K. Como-Sabetti, J. A. Jernigan, K. Harriman, L. H. Harrison, R. Lynfield, and M. M. Farley. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352:1436-1444.
11. Gruber, M. F. 2003. Non-clinical safety assessment of vaccines. Center for Biological Evaluation and Research, U.S. Food and Drug Administration, Washington, DC.
12. Hoen, B., F. Alla, C. Selton-Suty, I. Beguinot, A. Bouvet, S. Briancon, J. P. Casalta, N. Danchin, F. Delahaye, J. Etienne, V. Le Moing, C. Leport, J. L. Mainardi, R. Ruimy, and F. Vandenesch. 2002. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 288:75-81.
13. Ibrahim, A. S., B. J. Spellberg, V. Avanesian, Y. Fu, and J. E. Edwards, Jr. 2006. The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect. Immun. 74:3039-3041.
14. Ibrahim, A. S., B. J. Spellberg, V. Avenissian, Y. Fu, S. G. Filler, and J. E. Edwards, Jr. 2005. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. 73:999-1005.
15. Josefsson, E., O. Hartford, L. O'Brien, J. M. Patti, and T. Foster. 2001. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 184:1572-1580.
16. Lee, L. Y., Y. J. Miyamoto, B. W. McIntyre, M. Hook, K. W. McCrea, D. McDevitt, and E. L. Brown. 2002. The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell-mediated responses. J. Clin. Investig. 110:1461-1471.
17. Madrigal, A. G., L. Basuino, and H. F. Chambers. 2005. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3163-3165.
18. McLoughlin, R. M., J. C. Lee, D. L. Kasper, and A. O. Tzianabos. 2008. IFN-γ regulated chemokine production determines the outcome of Staphylococcus aureus infection. J. Immunol. 181:1323-1332.
19. Moran, G. J., A. Krishnadasan, R. J. Gorwitz, G. E. Fosheim, L. K. McDougal, R. B. Carey, and D. A. Talan. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
20. Nguyen, D. M., E. Bancroft, L. Mascola, R. Guevara, and L. Yasuda. 2007. Risk factors for neonatal methicillin-resistant Staphylococcus aureus infection in a well-infant nursery. Infect. Control Hosp. Epidemiol. 28:406-411.
21. Phan, Q. T., C. L. Myers, Y. Fu, D. C. Sheppard, M. R. Yeaman, W. H. Welch, A. S. Ibrahim, J. E. Edwards, and S. G. Filler. 2007. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol. 5:e64.
22. Rauceo, J. M., R. De Armond, H. Otoo, P. C. Kahn, S. A. Klotz, N. K. Gaur, and P. N. Lipke. 2006. Threonine-rich repeats increase fibronectin binding in the Candida albicans adhesin Als5p. Eukaryot. Cell 5:1664-1673.
23. Sasaki, S., S. Nishikawa, T. Miura, M. Mizuki, K. Yamada, H. Madarame, Y. I. Tagawa, Y. Iwakura, and A. Nakane. 2000. Interleukin-4 and interleukin-10 are involved in host resistance to Staphylococcus aureus infection through regulation of gamma interferon. Infect. Immun. 68:2424-2430.
24. Sasaki, S., Y. Tagawa, Y. Iwakura, and A. Nakane. 2006. The role of gamma interferon in acquired host resistance against Staphylococcus aureus infection in mice. FEMS Immunol. Med. Microbiol. 46:367-374.
25. Sattler, C. A., E. O. Mason, Jr., and S. L. Kaplan. 2002. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr. Infect. Dis. J. 21:910-917.
26. Sheppard, D. C., M. R. Yeaman, W. H. Welch, Q. T. Phan, Y. Fu, A. S. Ibrahim, S. G. Filler, M. Zhang, A. J. Waring, and J. E. Edwards, Jr. 2004. Functional and structural diversity in the Als protein family of Candida albicans. J. Biol. Chem. 279:30480-30489.
27. Smeltzer, M. S., F. L. Pratt, A. F. Gillaspy, and L. A. Young. 1996. Genomic fingerprinting for epidemiological differentiation of Staphylococcus aureus clinical isolates. J. Clin. Microbiol. 34:1364-1372.
28. Spellberg, B., S. G. Filler, and J. E. Edwards, Jr. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42:244-251.
29. Spellberg, B., A. S. Ibrahim, L. Lin, V. Avanesian, Y. Fu, P. Lipke, H. Otoo, T. Ho, and J. E. Edwards, Jr. 2008. Antibody titer threshold predicts anticandidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J. Infect. Dis. 197:967-971.
30. Spellberg, B. J., A. S. Ibrahim, V. Avanesian, Y. Fu, C. Myers, Q. T. Phan, S. G. Filler, M. R. Yeaman, and J. E. Edwards, Jr. 2006. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J. Infect. Dis. 194:256-260.
31. Spellberg, B. J., A. S. Ibrahim, V. Avenissian, S. G. Filler, C. L. Myers, Y. Fu, and J. E. Edwards, Jr. 2005. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect. Immun. 73:6191-6193.
32. Spellberg, B. J., D. Johnston, Q. T. Phan, J. E. Edwards, Jr., S. W. French, A. Ibrahim, and S. G. Filler. 2003. Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect. Immun. 71:5756-5764.
33. Stover, C. K., X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, I. T. Paulsen, J. Reizer, M. H. Saier, R. E. Hancock, S. Lory, and M. V. Olson. 2000. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406:959-964.
34. Taborda, C. P., J. Rivera, O. Zaragoza, and A. Casadevall. 2003. More is not necessarily better: prozone-like effects in passive immunization with IgG. J. Immunol. 170:3621-3630.
35. Vernachio, J., A. S. Bayer, T. Le, Y. L. Chai, B. Prater, A. Schneider, B. Ames, P. Syribeys, J. Robbins, and J. M. Patti. 2003. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob. Agents Chemother. 47:3400-3406.
36. Wei, X. Q., B. P. Leung, W. Niedbala, D. Piedrafita, G. J. Feng, M. Sweet, L. Dobbie, A. J. Smith, and F. Y. Liew. 1999. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J. Immunol. 163:2821-2828.
37. Wilson, L. S., C. M. Reyes, M. Stolpman, J. Speckman, K. Allen, and J. Beney. 2002. The direct cost and incidence of systemic fungal infections. Value Health 5:26-34.
38. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
39. Zhao, Y. X., I. M. Nilsson, and A. Tarkowski. 1998. The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology 93:80-85.